Introductory Chapter: Interactions between Environmental Chemicals and KRAS Oncogene in Different Cancers - Special Focus on Colorectal, Pancreatic, and Lung Cancers
Reference35 articles.
1. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17-33
2. Denis JA, Lacorte JM. Detection of RAS mutations in circulating tumor cells: Applications in colorectal cancer and prospects. Annales de Biologie Clinique. 2017;75(6):607-618
3. Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nature Reviews. Clinical Oncology. 2018;15(11):709-720
4. Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, et al. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Critical Reviews in Oncology/Hematology. 2018;125:69-77
5. Li D, Jiao L. Molecular epidemiology of pancreatic cancer. International Journal of Gastrointestinal Cancer. 2003;33(1):3-14